Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab.

Friedlander P, Wassmann K, Christenfeld AM, Fisher D, Kyi C, Kirkwood JM, Bhardwaj N, Oh WK.

J Immunother Cancer. 2017 Aug 15;5(1):67. doi: 10.1186/s40425-017-0272-z.

2.

Blood mRNA expression profiling predicts survival in patients treated with tremelimumab.

Saenger Y, Magidson J, Liaw B, de Moll E, Harcharik S, Fu Y, Wassmann K, Fisher D, Kirkwood J, Oh WK, Friedlander P.

Clin Cancer Res. 2014 Jun 15;20(12):3310-8. doi: 10.1158/1078-0432.CCR-13-2906. Epub 2014 Apr 10.

3.
4.

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, Guida M, Hyams DM, Gómez H, Bastholt L, Chasalow SD, Berman D.

J Transl Med. 2011 Nov 28;9:204. doi: 10.1186/1479-5876-9-204.

5.

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, Lorigan P, Kendra KL, Maio M, Trefzer U, Smylie M, McArthur GA, Dreno B, Nathan PD, Mackiewicz J, Kirkwood JM, Gomez-Navarro J, Huang B, Pavlov D, Hauschild A.

J Clin Oncol. 2013 Feb 10;31(5):616-22. doi: 10.1200/JCO.2012.44.6112. Epub 2013 Jan 7.

6.

Genetic basis for clinical response to CTLA-4 blockade in melanoma.

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, Hollmann TJ, Bruggeman C, Kannan K, Li Y, Elipenahli C, Liu C, Harbison CT, Wang L, Ribas A, Wolchok JD, Chan TA.

N Engl J Med. 2014 Dec 4;371(23):2189-2199. doi: 10.1056/NEJMoa1406498. Epub 2014 Nov 19.

7.

Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?

Ménard C, Ghiringhelli F, Roux S, Chaput N, Mateus C, Grohmann U, Caillat-Zucman S, Zitvogel L, Robert C.

Clin Cancer Res. 2008 Aug 15;14(16):5242-9. doi: 10.1158/1078-0432.CCR-07-4797.

8.

Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma.

Kirkwood JM, Lorigan P, Hersey P, Hauschild A, Robert C, McDermott D, Marshall MA, Gomez-Navarro J, Liang JQ, Bulanhagui CA.

Clin Cancer Res. 2010 Feb 1;16(3):1042-8. doi: 10.1158/1078-0432.CCR-09-2033. Epub 2010 Jan 19.

9.

Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.

Eroglu Z, Kim DW, Wang X, Camacho LH, Chmielowski B, Seja E, Villanueva A, Ruchalski K, Glaspy JA, Kim KB, Hwu WJ, Ribas A.

Eur J Cancer. 2015 Nov;51(17):2689-97. doi: 10.1016/j.ejca.2015.08.012. Epub 2015 Sep 10.

10.

Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion.

Ribas A, Chesney JA, Gordon MS, Abernethy AP, Logan TF, Lawson DH, Chmielowksi B, Glaspy JA, Lewis K, Huang B, Wang E, Hsyu PH, Gomez-Navarro J, Gerhardt D, Marshall MA, Gonzalez R.

J Transl Med. 2012 Nov 21;10:236. doi: 10.1186/1479-5876-10-236.

11.

Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours.

Millward M, Underhill C, Lobb S, McBurnie J, Meech SJ, Gomez-Navarro J, Marshall MA, Huang B, Mather CB.

Br J Cancer. 2013 May 28;108(10):1998-2004. doi: 10.1038/bjc.2013.227. Epub 2013 May 7.

12.

Clinical development of the anti-CTLA-4 antibody tremelimumab.

Ribas A.

Semin Oncol. 2010 Oct;37(5):450-4. doi: 10.1053/j.seminoncol.2010.09.010. Review.

PMID:
21074059
13.

Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma.

Koyanagi K, O'Day SJ, Boasberg P, Atkins MB, Wang HJ, Gonzalez R, Lewis K, Thompson JA, Anderson CM, Lutzky J, Amatruda TT, Hersh E, Richards J, Weber JS, Hoon DS.

Clin Cancer Res. 2010 Apr 15;16(8):2402-8. doi: 10.1158/1078-0432.CCR-10-0037. Epub 2010 Apr 6.

14.

Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.

Brüggemann C, Kirchberger MC, Goldinger SM, Weide B, Konrad A, Erdmann M, Schadendorf D, Croner RS, Krähenbühl L, Kähler KC, Hafner C, Leisgang W, Kiesewetter F, Dummer R, Schuler G, Stürzl M, Heinzerling L.

J Cancer Res Clin Oncol. 2017 Oct;143(10):1977-1984. doi: 10.1007/s00432-017-2450-2. Epub 2017 Jun 14.

PMID:
28616701
15.

Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.

Larkin J, Lao CD, Urba WJ, McDermott DF, Horak C, Jiang J, Wolchok JD.

JAMA Oncol. 2015 Jul;1(4):433-40. doi: 10.1001/jamaoncol.2015.1184.

PMID:
26181250
16.

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.

Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, Zhao X, Martinez AJ, Wang W, Gibney G, Kroeger J, Eysmans C, Sarnaik AA, Chen YA.

J Clin Oncol. 2013 Dec 1;31(34):4311-8. doi: 10.1200/JCO.2013.51.4802. Epub 2013 Oct 21.

17.

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?

Mangana J, Cheng PF, Schindler K, Weide B, Held U, Frauchiger AL, Romano E, Kähler KC, Rozati S, Rechsteiner M, Moch H, Michielin O, Garbe C, Hauschild A, Hoeller C, Dummer R, Goldinger SM.

PLoS One. 2015 Oct 1;10(10):e0139438. doi: 10.1371/journal.pone.0139438. eCollection 2015.

18.

Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study).

Busse A, Rapion J, Fusi A, Suciu S, Nonnenmacher A, Santinami M, Kruit WH, Testori A, Punt CJ, Dalgleish AG, Spatz A, Eggermont AM, Keilholz U.

Cancer Immunol Immunother. 2013 Jul;62(7):1223-33. doi: 10.1007/s00262-013-1428-4. Epub 2013 Apr 27.

PMID:
23624802
19.

A phase 2 study of tremelimumab in patients with advanced uveal melanoma.

Joshua AM, Monzon JG, Mihalcioiu C, Hogg D, Smylie M, Cheng T.

Melanoma Res. 2015 Aug;25(4):342-7. doi: 10.1097/CMR.0000000000000175.

PMID:
26050146
20.

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.

Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C.

JAMA. 2016 Apr 19;315(15):1600-9. doi: 10.1001/jama.2016.4059. Erratum in: JAMA. 2016 Jun 14;315(22):2472.

PMID:
27092830

Supplemental Content

Support Center